Aclarion, Inc. (NASDAQ:ACON) Sees Large Decline in Short Interest

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a significant decline in short interest in March. As of March 13th, there was short interest totaling 142,742 shares, a decline of 14.4% from the February 26th total of 166,784 shares. Approximately 16.9% of the company’s stock are short sold. Based on an average daily volume of 92,421 shares, the short-interest ratio is presently 1.5 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ACON shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Aclarion from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Aclarion Stock Performance

Shares of Aclarion stock opened at $3.08 on Tuesday. Aclarion has a one year low of $2.34 and a one year high of $13.69. The company has a market cap of $7.02 million, a PE ratio of -0.18 and a beta of 1.44. The business has a 50-day simple moving average of $3.06 and a 200-day simple moving average of $5.47.

Aclarion (NASDAQ:ACON) last released its earnings results on Wednesday, March 18th. The company reported ($2.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.60) by $1.59. Aclarion had a negative net margin of 9,517.11% and a negative return on equity of 52.31%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. On average, sell-side analysts predict that Aclarion will post -263.33 earnings per share for the current fiscal year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.